Agencia Europea de Medicamentos. Ficha Técnica Remicade (Infliximab).

Van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric crohn’s disease: an ECCO-ESPGHAN Guideline Update. J Crohn’s Colitis. 2021;15(2):171–94.

Article  Google Scholar 

Santacana E, Rodríguez-Alonso L, Padullés A, Guardiola J, Rodríguez-Moranta F, Serra K, et al. External evaluation of population pharmacokinetic models of infliximab in patients with inflammatory bowel disease. Ther Drug Monit. 2018;40(1):120–9.

Article  CAS  PubMed  Google Scholar 

Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946–64.

Article  CAS  PubMed  Google Scholar 

Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petitcollin A, Leuret O, Tron C, Lemaitre F, Verdier M-C, Paintaud G, et al. Modeling immunization to infliximab in children with Crohn’s disease using population pharmacokinetics: a pilot study. Inflamm Bowel Dis. 2018;24(8):1745–54.

Bauman LE, Xiong Y, Mizuno T, Minar P, Fukuda T, Dong M, et al. Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(3):429–39.

Article  PubMed  Google Scholar 

Xiong Y, Mizuno T, Colman R, Hyams J, Noe JD, Boyle B, et al. Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with crohn’s disease. Clin Pharmacol Ther. 2021;109(6):1639–47.

Schräpel C, Kovar L, Selzer D, Hofmann U, Tran F, Reinisch W, et al. External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease. Pharmaceutics. 2021;13(9):1368.

Konecki C, Feliu C, Cazaubon Y, Giusti D, Tonye-Libyh M, Brixi H, et al. External evaluation of population pharmacokinetic models and bayes-based dosing of infliximab. Pharmaceutics. 2021;13(8):1–20.

Article  Google Scholar 

Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, et al. Development and internal validation of a model using fecal calprotectin in combination with infliximab trough levels to predict clinical relapse in Crohn’s disease. Inflamm Bowel Dis. 2017;23(1):126–32.

Article  PubMed  Google Scholar 

Beltrán B, Iborra M, Sáez-González E, Marqués-Miñana MR, Moret I, Cerrillo E, et al. Fecal calprotectin pretreatment and induction infliximab levels for prediction of primary nonresponse to infliximab therapy in Crohn’s disease. Dig Dis. 2019;37(2):108–15.

Article  PubMed  Google Scholar 

Engström J, Lönnkvist M, Befrits R, Ljung T, Diaz-Tartera H, Holst M, et al. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy. Scand J Gastroenterol. 2019;54(9):1081–8.

Article  PubMed  Google Scholar 

Salvador-Martín S, Pujol-Muncunill G, Bossacoma F, Navas-López VM, Gallego-Fernández C, Segarra O, et al. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease. Br J Clin Pharmacol. 2021;87(2):447–57.

Article  PubMed  Google Scholar 

Bek S, Nielsen JV, Bojesen AB, Franke A, Bank S, Vogel U, et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44(6):554–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020;158(1):189–99.

Article  CAS  PubMed  Google Scholar 

Salvador-Martín S, Zapata-Cobo P, Velasco M, Palomino LM, Clemente S, Segarra O, et al. Association between HLA DNA variants and long-term response to anti-TNF drugs in a Spanish pediatric inflammatory bowel disease cohort. Int J Mol Sci. 2023;24(2):1797. https://doi.org/10.3390/ijms24021797.

Laserna-Mendieta EJ, Salvador-Martín S, Arias A, López-Cauce B, Marín-Jiménez I, Menchén LA, et al. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn’s disease. Biomed Pharmacother. 2023;159:114225. https://doi.org/10.1016/j.biopha.2023.114225.

Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm Bowel Dis. 2011;17(6):1314–21.

Article  PubMed  Google Scholar 

Beal SL, Sheiner LB, Boeckmann AJ et al. NONMEM 7.1.0 users guides. Ellicott City: Icon Development Solutions; 1989–2009

Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36.

Largajolli A, Bertoldo A, Campioni M, Cobelli C. Visual predictive check in models with time-varying input function. AAPS J. 2015;17(6):1455–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.

Article  PubMed  PubMed Central  Google Scholar 

Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, et al. Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn’s disease. Clin Gastroenterol Hepatol. 2020;18(3):637-646.e11.

Article  CAS  PubMed  Google Scholar 

Kooloos WM. Potential role of pharmacogenetics for optimalization of drug therapy in rheumatoid arthritis. 2009. Retrieved from: https://scholarlypublications.universiteitleiden.nl/access/item%3A2927553/view. Accessed 20 Jan 2024.

Salvador-Martín S, Kaczmarczyk B, Álvarez R, Navas-López VM, Gallego-Fernández C, Moreno-álvarez A, et al. Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease. Pharmaceutics. 2021;13(1):1–17.

Article  Google Scholar 

Salvador-Martín S, Raposo-Gutiérrez I, Navas-López VM, Gallego-Fernández C, Moreno-álvarez A, Solar-Boga A, et al. Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease. Int J Mol Sci. 2020;21(9):3364. https://doi.org/10.3390/ijms21093364.

Salvador-Martín S, Bossacoma F, Pujol-Muncunill G, Navas-López VM, Gallego-Fernández C, Viada J, et al. Genetic predictors of long-term response to antitumor necrosis factor agents in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2020;71(4):508–15.

Article  PubMed  Google Scholar 

Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for optimization and personalization of anti-tnfs in pediatric inflammatory bowel disease. Pharmaceutics. 2021;13(11):1–16.

Article  Google Scholar